Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy

OBJECTIVES: The safety and efficacy of sirukumab, an anti-interleukin-6 (IL-6) monoclonal antibody, were evaluated in a 2-part, placebo-controlled phase II study of patients with active rheumatoid arthritis (RA) despite methotrexate therapy. METHODS: In Part A (proof-of-concept), 36 patients were ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Smolen, Josef S, Weinblatt, Michael E, Sheng, Shihong, Zhuang, Yanli, Hsu, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145446/
https://www.ncbi.nlm.nih.gov/pubmed/24699939
http://dx.doi.org/10.1136/annrheumdis-2013-205137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145446/
https://www.ncbi.nlm.nih.gov/pubmed/24699939
http://dx.doi.org/10.1136/annrheumdis-2013-205137

Ejemplares similares